Abbott Laboratories (ABT) announced that it had received a CE mark for its high sensitivity troponin-I blood test on September 26. The test is the first CE mark troponin test in the industry that can be used to predict the possibility of a cardiac event in advance for an apparently healthy adult.
The test can predict an event as early as a few months or a few years in advance. Abbott’s troponin blood test uses a biomarker specific to the heart.
Cardiovascular diseases cause the highest number of deaths in the world. However, diagnostic tests such as the troponin test can help in the early detection of a possible cardiac event, which can then be prevented by lifestyle changes and medication. Thus, Abbott’s troponin test has huge market potential. In the second quarter, Abbott registered Diagnostics segment sales of $1.9 billion, up 6.6% year-over-year on an organic basis.
On September 26, ABT stock registered a rise of ~0.89% compared to its previous day’s closing price.
Research shows better diagnosis with the troponin test
Currently, for the detection of the possibility of a cardiac event, it’s recommended that doctors consider factors such as cholesterol levels, diabetes levels, blood pressure, and the smoking habits of the patient, as per European guidelines.
However, according to Abbott, “A substantial body of research has shown that measuring a person’s troponin levels using Abbott’s High Sensitive Troponin-I test provides better predictive information for determining a person’s chances of developing future heart disease when added to the current standard of care.”